Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA updates Repros on Proellex clinical hold

This article was originally published in Scrip

Executive Summary

The US FDA has provided Repros Therapeutics with further clarification over the full clinical hold status of its lead drug, the orally selective progesterone antagonist Proellex, and guidance for the company to get the hold lifted. The drug was being looked at for the treatment of chronic symptomatic uterine fibroids and associated anaemia, as well as endometriosis.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel